The results of scRNA-seq revealed that when some liver cancer patients were not treated with sorafenib, the JUN family genes in some liver cancer cells were over-activated, and the HIF pathway was metabolized through the high interaction between ALB and FcRn. This evidence concerns the gene ALB and liver cancer.